USP36 inhibits apoptosis by deubiquitinating cIAP1 and survivin in colorectal cancer cells
Journal of Biological Chemistry · 2024
DOI: 10.1016/j.jbc.2024.107463 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2024. Verfasst von Bao Gao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, First Hospital of Jilin University, Changchun, Jilin, China; Laboratory for Tumor Immunology, First Hospital of Jilin University, Chan…. Hauptthemen laut MEDLINE: Apoptosis, Colorectal Neoplasms, Inhibitor of Apoptosis Proteins, Survivin. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Chemotherapeutic agents for treating colorectal cancer (CRC) primarily induce apoptosis in tumor cells. The ubiquitin-proteasome system is critical for apoptosis regulation. Deubiquitinating enzymes (DUBs) remove ubiquitin from substrates to reverse ubiquitination. Although over 100 DUB members have been discovered, the biological functions of only a small proportion of DUBs have been characterized. Here, we aimed to systematically identify the DUBs that contribute to the development of CRC. Among the DUBs, ubiquitin-specific protease 36 (USP36) is upregulated in CRC. We showed that the knockdown of USP36 induces intrinsic and extrinsic apoptosis. Through gene silencing and coimmunoprecipitation techniques, we identified survivin and cIAP1 as USP36 targets. Mechanistically, USP36 binds and removes lysine-11-linked ubiquitin chains from cIAP1 and lysine-48-linked ubiquitin chains from survivin to abolish protein degradation. Overexpression of USP36 disrupts the formation of the XIAP-second mitochondria-derived activator of caspase complex and promotes receptor-interacting protein kinase 1 ubiquitination, validating USP36 as an inhibitor to intrinsic and extrinsic apoptosis through deubiquitinating survivin and cIAP1. Therefore, our results suggest that USP36 is involved in CRC progression and is a potential therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Center, First Hospital of Jilin University, Changchun, Jilin, China; Laboratory for Tumor Immunology, First Hospital of Jilin University, Changchun, Jilin, China.
- Laboratory for Tumor Immunology, First Hospital of Jilin University, Changchun, Jilin, China.
- Laboratory for Tumor Immunology, First Hospital of Jilin University, Changchun, Jilin, China. Electronic address: yjliuanderson@jlu.edu.cn.
- Cancer Center, First Hospital of Jilin University, Changchun, Jilin, China; Laboratory for Tumor Immunology, First Hospital of Jilin University, Changchun, Jilin, China. Electronic address: jtchen@jlu.edu.cn.
Zitieren
APA
Gao, B., Qiao, Y., Zhu, S., Yang, N., Zou, S. S., Liu, Y. J., & Chen, J. (2024). USP36 inhibits apoptosis by deubiquitinating cIAP1 and survivin in colorectal cancer cells. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2024.107463
Vancouver
Gao B, Qiao Y, Zhu S, Yang N, Zou SS, Liu YJ, et al. USP36 inhibits apoptosis by deubiquitinating cIAP1 and survivin in colorectal cancer cells. Journal of Biological Chemistry. 2024. doi:10.1016/j.jbc.2024.107463
BibTeX
@article{Gao2024,
author = {Gao, Bao and Qiao, Yuan and Zhu, Shan and Yang, Ning and Zou, Shan-Shan and Liu, Yong-Jun and Chen, Jingtao},
title = {USP36 inhibits apoptosis by deubiquitinating cIAP1 and survivin in colorectal cancer cells},
journal = {Journal of Biological Chemistry},
year = {2024},
doi = {10.1016/j.jbc.2024.107463}
}
EUVIMED